ArticleOpen forum infectious diseases2021

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.

Nicholas Rebold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.